EQRx (EQRX) Cash-to-Debt : 588.50 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is EQRx Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. EQRx's cash to debt ratio for the quarter that ended in Sep. 2023 was 588.50.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, EQRx could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for EQRx's Cash-to-Debt or its related term are showing as below:

EQRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 96.3 Med: 388.71 Max: 617.45
Current: 588.5

During the past 4 years, EQRx's highest Cash to Debt Ratio was 617.45. The lowest was 96.30. And the median was 388.71.

EQRX's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.5 vs EQRX: 588.50

EQRx Cash-to-Debt Historical Data

The historical data trend for EQRx's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

EQRx Cash-to-Debt Chart

EQRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

0.71

96.30

497.49

365.25

EQRx Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial								329.09	365.25	412.17	476.96	588.50

Competitive Comparison of EQRx's Cash-to-Debt

For the Biotechnology subindustry, EQRx's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EQRx's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EQRx's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where EQRx's Cash-to-Debt falls into.

EQRx Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

EQRx's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1399.286	/	(2.37	+	1.461)
	=	365.25

EQRx's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1212.3	/	(2.06	+	0)
	=	588.50

EQRx (NAS:EQRX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

EQRx Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of EQRx's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

EQRx (EQRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EQRx Inc (NAS:EQRX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Hampshire Street, Cambridge, MA, USA, 02139

Website

https://www.eqrx.com

EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.

Executives

Dina Ciarimboli	officer: General Counsel and Secretary	EQRX, INC., 50 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Clive Meanwell	director	THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Andreessen Horowitz Lsv Fund I-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Bio Ii, L.l.c.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Lsv Ii, L.l.c.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-q, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Krishna Yeshwant	director	C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Kathryn E Giusti	director	1499 POST ROAD, FAIRFIELD CT 06824
Melanie Nallicheri	director, officer: Chief Executive Officer	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Ah Bio Fund Iii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025